SCHEMBL648526

SCHEMBL648526

O=C(O)c1cc2cc(O)ccc2o1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.76
LMNA P02545 2/20 0.71
KDM4E B2RXH2 1/20 0.71
ALDH1A1 P00352 1/20 0.71
GLA P06280 1/20 0.71
GAA P10253 1/20 0.71
HPGD P15428 1/20 0.71
CASP1 P29466 1/20 0.71
BRCA1 P38398 1/20 0.71
CASP7 P55210 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
HSD17B10 Q99714 1/20 0.71
CLK1 P49759 2/20 0.67
DYRK1A Q13627 2/20 0.67
DYRK1B Q9Y463 2/20 0.67
PIM1 P11309 6/20 0.66
MAOA P21397 1/20 0.62
TP53 P04637 1/20 0.61
PIM2 Q9P1W9 1/20 0.60
CA2 P00918 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31060304 0.86 FLT3 (1.00) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL28795137 0.86 FLT3 (1.00) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL11456119 0.86 PIM1 (0.61) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL29431747 0.85 FLT3 (0.76) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL10508628 0.85 FLT3 (0.76) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL6407371 0.85 FLT3 (0.76) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL30402838 0.83 KDM4E (1.00) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL1390692 0.83 KDM4E (1.00) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL9989803 0.83 FLT3 (0.73) FLT3LMNAKDM4EALDH1A1GLA
SCHEMBL3379125 0.81 CLK1 (0.82) FLT3LMNAKDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256104-A1 substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation SMITHKLINE BEECHAM CORPORATION 2005-11-17 US claimed
EP-1384713-A1 4-amino-azepan-3-one derivatives as protease inhibitors SmithKline Beecham Corporation (US) 2004-01-28 EP claimed
US-20040002487-A1 Protease inhibitors MARQUIS ROBERT WELLS (US) 2004-01-01 US claimed
US-20030225061-A1 Protease inhibitors MARQUIS ROBERT WELLS (US) 2003-12-04 US claimed
US-20030144175-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2003-07-31 US claimed
US-20030044399-A1 Method of treatment SMITHKLINE BEECHAM CORPORATION 2003-03-06 US claimed
US-20020147188-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-10 US claimed
EP-1158986-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2002-03-27 EP claimed
EP-1158986-A1 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2001-12-05 EP claimed
WO-2000038687-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-06 WO claimed
US-20260028334-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2026-01-29 US disclosed
CN-115703736-B Multi-target inhibitor targeting HDAC and NAD synthesis and application thereof 中国海洋大学 2025-05-16 CN disclosed
EP-4504723-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2025-02-12 EP disclosed
CN-118974040-A N- (3- (benzo [ B ] thiophen-2-amido) -phenyl) -2, 3-dihydrobenzo [ B ] [1,4] dioxin-6-amide derivatives and related compounds as lactic acid/ATP production inhibitors for the treatment of cancer 威马特股份公司 2024-11-15 CN disclosed
US-20240327418-A1 MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR OCEAN UNIVERSITY OF CHINA (CN) 2024-10-03 US disclosed
EP-0703911-A1 SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS PFIZER (US) 1996-04-03 EP disclosed
WO-1994029290-A1 SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS PFIZER INC. (US) 1994-12-22 WO disclosed
EP-0150966-B1 BENZOPYRAN DERIVATIVES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION FISONS plc (GB) 1989-07-12 EP disclosed
US-4670452-A Dioxo dibenzopyrans and anti-allergic use thereof FISONS PLC (GB) 1987-06-02 US disclosed
EP-0150966-A2 Benzopyran derivatives, compositions containing them and processes for their preparation FISONS plc (GB) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225061-A1 Protease inhibitors CTSK, MMP13, CTSZ FLT3 3182/4885LMNA 2800/4885KDM4E 917/4885
US-20030044399-A1 Method of treatment DNPEP, PEPD, ANPEP FLT3 2030/4885LMNA 3319/4885KDM4E 956/4885
US-20240327418-A1 MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR HDAC3, HDAC1, HDAC11 FLT3 2701/4885LMNA 867/4885KDM4E 448/4885
US-20050256104-A1 substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation CTSK, CTSZ, CTSE FLT3 1852/4885LMNA 3527/4885KDM4E 875/4885
US-20020147188-A1 Protease inhibitors CTSK, MMP13, CTSZ FLT3 3182/4885LMNA 2800/4885KDM4E 917/4885
US-20040002487-A1 Protease inhibitors CTSK, MMP13, CTSZ FLT3 3182/4885LMNA 2800/4885KDM4E 917/4885
US-20030144175-A1 Protease inhibitors CTSK, MMP13, CTSZ FLT3 3182/4885LMNA 2800/4885KDM4E 917/4885
US-20260028334-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER LDHA, LDHB, SLC6A1 FLT3 3793/4885LMNA 1253/4885KDM4E 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.